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O B J E C T I V E S The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer,
with glimepiride, an insulin secretagogue, on atherosclerotic plaque inﬂammation by using serial
18F-ﬂuorodeoxyglucose positron emission tomography (FDG-PET) imaging.
B A C KG ROUND Atherosclerosis is intrinsically an inﬂammatory disease. Although hyperglycemia is
associated with an increased risk of atherosclerotic cardiovascular disease, there are no clinical data to show
the preference of any speciﬁc oral hypoglycemic agents to prevent atherosclerotic plaque inﬂammation.
METHOD S A total of 56 impaired glucose tolerant or diabetic patients with carotid atherosclerosis
underwent a complete history, determinations of blood chemistries, anthropometric variables, and
FDG-PET. They were randomly assigned to receive either pioglitazone (15 to 30 mg) or glimepiride (0.5
to 4.0 mg) for 4 months with titration to optimal dosage. Effects of the drugs on atherosclerotic plaque
inﬂammation were evaluated by FDG-PET at study completion. Plaque inﬂammation was measured by
blood-normalized standardized uptake value, known as a target-to-background ratio.
R E S U L T S The study was completed in 31 pioglitazone-treated patients and 21 glimepiride-treated patients.
Although both treatments reduced fasting plasma glucose and hemoglobin A1c values comparably, pioglitazone,
but not glimepiride, decreased atherosclerotic plaque inﬂammation. Compared with glimepiride, pioglitazone
signiﬁcantly increased high-density lipoprotein cholesterol level. High-sensitivity C-reactive protein was decreased
by pioglitazone, whereas it was increased by glimepiride. Multiple stepwise regression analysis revealed that the
increase in high-density lipoprotein cholesterol level was independently associatedwith the attenuation of plaque
inﬂammation.
CONC L U S I O N S Our present study suggests that pioglitazone could attenuate atherosclerotic plaque
inﬂammation in patients with impaired glucose tolerance or in diabetic patients independent of glucose lowering
effect. Pioglitazone may be a promising strategy for the treatment of atherosclerotic plaque inﬂammation in
impaired glucose tolerance or diabetic patients. (Detection of Plaque Inﬂammation and Visualization of Anti-
Inﬂammatory Effects of Pioglitazone on Plaque Inﬂammation in Subjects With Impaired Glucose Tolerance and
Type 2 Diabetes Mellitus by FDG-PET/CT; NCT00722631) (J Am Coll Cardiol Img 2011;4:1110–8) © 2011 by the
American College of Cardiology Foundation
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1111ioglitazone, one of the peroxisome proliferator-
activated receptor gamma agonists, is a widely
used drug for the treatment of diabetes mellitus.
It improves insulin resistance and subsequently
ecreases plasma glucose as well as hemoglobin
Hb) A1c values in patients with diabetes (1).
urther, pioglitazone is reported to exert other
See page 1119
beneficial metabolic effects in diabetic patients; it
not only decreases blood pressure levels, but also
improves lipid profiles in insulin-resistant subjects
(2–4). Recent clinical studies have suggested that
pioglitazone may have atheroprotective properties
in humans (5–9). The CHICAGO (Carotid Intima
Media Thickness in Atherosclerosis Using Piogli-
tazone) study and the PERISCOPE (Pioglitazone
Effect on Regression of Intravascular Sonographic
Coronary Obstruction Prospective Evaluation) study
ave revealed that pioglitazone is better than
limepiride, an insulin secretagogue, for preventing
he progression of atherosclerosis in patients with
iabetes (8,9). Furthermore, in the PROactive (PRO-
pective pioglitazone clinical trial in macrovascular
Events) trial, pioglitazone remarkably reduced
stroke among high-risk type 2 diabetic patients in
such a short period after starting treatment, sug-
gesting a possible plaque stabilizing effect of piogli-
tazone (5–7). However, whether atheroprotective
properties of pioglitazone in diabetic subjects could
be dependent of its glucose-lowering effects or
mediated by its pleiotropic actions remains un-
known.
Atherosclerosis is intrinsically an inflammatory dis-
ease (10–16). Indeed, atherosclerotic plaques contain
numerous inflammatory cells, particularly macro-
phages, which could secrete a variety of growth fac-
tors, cytokines, and enzymes and subsequently con-
tribute to weakening of the fibrous cap of plaques
(12–16). Thus, blockade of inflammatory reactions
in the atherosclerotic plaques may be a therapeutic
target for preventing cardiovascular disease in pa-
tients with impaired glucose tolerance (IGT) or
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protective properties of pioglitazone, we examined
here whether and how pioglitazone could attenuate
atherosclerotic plaque inflammation in patients
with IGT or type 2 diabetes by using serial 18F-
fluorodeoxyglucose positron emission tomography
(FDG-PET) imaging.
M E T H O D S
Design and subjects. This study was a prospective,
randomized, comparator-controlled, 4-month
single-center trial involving 4 months of study-drug
administration and follow-up. Fifty-six patients
with IGT or type 2 diabetes who had ultrasono-
graphic evidence of atherosclerosis and FDG up-
take within atherosclerotic plaque were
enrolled. The study protocol was approved
by the ethics committee of Kurume Uni-
versity. All subjects provided written in-
formed consent.
We excluded any patients with uncon-
trolled diabetes (fasting blood glucose
200 mg/dl), with insulin treatment, with
left ventricular dysfunction (left ventricu-
lar ejection fraction40%) or heart failure
(New York Heart Association functional
class II), with symptomatic coronary
artery disease or symptomatic stroke within
at least 6 months before enrollment, with
neoplastic disorders, with active inflamma-
tory disease, and with a history of hypersen-
sitivity reactions to iodinated contrast media.
Four patients met the exclusion criteria.
Baseline and follow-up FDG-PET exami-
nations were available in 52 patients (93%,
68  8 years of age; 39 males, 13 females).
The disposition of patients in the study is
shown in Figure 1.
Treatment. Eligible patients were randomly as-
igned to receive either pioglitazone (n 31), 15 to
30 mg daily, or glimepiride (n  21), 0.5 to 4.0 mg
aily, as an active comparator for 4 months, in
ddition to their existing medications for diabetes.
he initial study drug dose was based on fasting
lucose level. Study drug doses were titrated to
each and maintain target glycemic goals defined as
fasting plasma glucose (FPG) level of 110 mg/dl
r lower. If patients were taking any medications
uch as antidiabetic medications, antiplatelet
gents, hypertensive medications, or statins, all of
he medications were not altered within the past 4
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1112Data collection. The medical history and smoking
istory were ascertained by a questionnaire. Smok-
ng was classified as current habitual use or not.
aist circumference was measured as an index of
entral obesity. Blood pressure was measured in the
itting position using an upright standard sphygmo-
anometer. Vigorous physical activity and smoking
ere avoided for at least 30 min before blood
ressure and resting heart rate measurements.
Blood was drawn after 12-h fasting from the
ntecubital vein in the morning for determinations of
ipid profiles, total cholesterol, low-density lipoprotein
holesterol (LDL-C), triglycerides, and high-density
ipoprotein cholesterol (HDL-C), FPG, fasting
lasma insulin, glycosylated hemoglobin (HbA1c),
nd high-sensitivity C-reactive protein (hsCRP).
hese blood chemistries were measured with standard
ethods at a commercially available laboratory
Kyodo Igaku Laboratory, Fukuoka, Japan) as de-
cribed previously (17–19).
FDG-PET/computed tomography imaging. Vascular
DG-PET imaging was performed as described
reviously (17–20). In brief, after at least 12 h of
asting, the study patients received an intravenous
dministration of FDG (4.2 MBq [0.12 mCi]/kg
ody weight) through the antecubital vein. Three
ours after the FDG injection, contrast medium on
dose-by-weight basis was administered, and
-dimensional whole-body PET imaging was car-
ied out using an integrated full-ring PET/
omputed tomography (CT) scanner (Gemini-
XL 16, Philips Medical Systems, Inc., Cleveland,
Figure 1. Disposition of Patients
Eligible patients were randomly assigned to receive either pioglitaz
comparator for 4 months, 31 in the pioglitazone group and 21 in t
ﬂuorodeoxyglucose; PET  positron emission tomography.hio). Sixteen-slice multidetector CT was used inhis study. For the contrast-enhanced scan, 100 ml
ontrast media (Iohexol, Daiichi Sankyo, Tokyo,
apan) was injected at 3.0 ml/s with biphasic injec-
ion of a 20-ml saline chaser. The CT data were
sed for attenuation correction and lesion localization.
fter both the transmission and emission images were
btained, the images were reconstructed using the
-dimensional line-of-response row-action maximum
ikelihood algorithm (3D-LOR-RAMLA, Philips,
indhoven, the Netherlands).
The intensity of FDG uptake was quantified by
easuring the standardized uptake value (SUV) cor-
ected for body weight. The SUV was calculated by
sing the maximum pixel activity value within the region
f interest placed on the entire vasculature obtained from
he consecutive coregistered transaxial FDG-PET and
ontrast-enhanced CT images. Analyses were performed
n common carotid arteries and ascending aorta of the
ortic arch because these vessels are responsible for
therothrombotic stroke (Fig. 2). The SUV score was
etermined as the average of the SUVs of both the
ommon carotid arteries and thoracic aorta obtained
rom consecutive PET/CT images, each separated by 4
m in length. The SUV score of artery was corrected for
lood activity by dividing the average blood SUV esti-
ated from the inferior vena cava to produce a blood-
orrected artery SUV, also known as target-to-
ackground ratio (TBR). Two blinded radiologists
easured the TBR values. The intraobserver or interob-
erver variability of TBR measurements was 5%.
Statistical methods. Data were presented as means 
SD or medians with the interquartile range. Differ-
15 to 30 mg daily or glimepiride 0.5 to 4.0 mg daily as an active
limepiride group. CT  computed tomography; FDG  18F-one
he gences between the 2 groups were tested using
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1113parametric or nonparametric tests. First, a paired t
test was performed for comparisons between base-
line and post-treatment. Second, the changes from
baseline were compared by unpaired t test between
the 2 groups. Statistical significance was defined as
p  0.05. All statistical analyses were performed
with the use of the SPSS system (SPSS Inc.,
Chicago, Illinois).
R E S U L T S
Clinical characteristics. Demographic characteristics
t baseline are shown in Table 1. There were no
ignificant differences of baseline data between the
groups including anthropometric, metabolic, he-
odynamic, and inflammatory variables. Previous
acrovascular morbidities and concomitant medi-
ations were well balanced in the 2 groups. More
han 50% of both groups’ patients had angiographi-
ally documented coronary artery disease. The ma-
ority of patients had hypertension and dyslipide-
ia. Approximately one-half of the patients were
eceiving statins, and 60% of the patients were
eceiving renin-angiotensin system inhibitors.
Treatment effects of pioglitazone and glimepiride on
laboratory results. All 52 patients completed the pro-
ocol. Thirty-one patients received pioglitazone, and
1 received glimepiride. The mean titrated daily dos-
ge of glimepiride was 1.4 mg, and that of pioglita-
one, 16.5 mg. Both treatments were well tolerated,
nd there was no episode of severe hypoglycemia.
able 2 summarizes clinical variables at baseline and
ollow-up for both treatment groups. After 4-month
reatment, FPG and HbA1c values were reduced
omparably in the 2 groups. Weight and waist cir-
umference were significantly increased by pioglita-
Figure 2. Analyses of FDG Activity
Analyses of 18F-ﬂuorodeoxyglucose (FDG) activity were quantiﬁed o
arch (right), which are responsible for atherothrombotic stroke.one treatment. A significant increase in HDL-C was (bserved after 4 months of treatment only in the piogli-
azone group. Pioglitazone significantly decreased
sCRP level (0.78 [0.37–2.07] mg/l to 0.51 [0.26–1.02]
g/l, p  0.01), whereas glimepiride significantly in-
reased it (0.72 [0.41–1.51] mg/l to 1.04 [0.50–2.10]
g/l, p 0.05). In both groups, no significant changes
were observed for blood pressure, fasting plasma insulin,
LDL-C, or triglycerides during the study period.
Treatment effects on FDG-PET/CT image. There was
o significant difference in baseline TBR between the
groups. Figure 3 represents images of the transaxial
coregistration of FDG-PET and contrast-enhanced
CT, and focuses on the carotid arteries using CT and
FDG-PET/CT in patients with glimepiride and
pioglitazone treatments. At baseline (Fig. 3, left
panels), the FDG uptakes were seen in the eccen-
trically protruding arterial walls, suggesting the
FDG uptakes reflect atherosclerotic plaque inflam-
mation. After 4 months of treatment, pioglitazone
attenuated FDG activity within atherosclerotic
plaques, but glimepiride did not (Fig. 3). In quan-
titative analysis, TBR values were significantly re-
duced in the pioglitazone group (1.46  0.29 to
1.32  0.22, p  0.01), but were substantially
increased in the glimepiride group (1.35  0.26 to
1.41  0.30, p  NS) (Fig. 4, top). Also, the TBR
change from baseline was significantly greater in the
pioglitazone group than in the glimepiride group (p
0.01) (Fig. 4, bottom).
Association analyses. Table 3 demonstrates factors
associated with the absolute change () of TBR by
univariate analysis and multiple stepwise regression
analysis in all subjects. A statistical significance was
demonstrated between TBR and hs-CRP (p 
0.05) or HDL-C (p 0.02) by univariate analysis
mmon carotid arteries (left) and ascending aorta of the aorticn coTable 3). Because these significant parameters
s

F
w
i
T
f
signiﬁcant.
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1114could be closely correlated with each other, we
performed multiple stepwise regression analysis to
determine independent correlates of TBR. As
shown in Table 3, HDL-C (p  0.01) remained
ignificant and was independently correlated to
TBR (R2  0.143). We analyzed the data of the
pioglitazone group in which TBR was significantly
decreased. Consistent with the results of whole
population, HDL-C was independently and sig-
nificantly correlated to TBR (p  0.05, R2  0.146)
by multiple stepwise regression analysis.
D I S C U S S I O N
In our prospective, randomized, comparator-
controlled clinical study, we demonstrated for the
first time that, compared with glimepiride, piogli-
tazone significantly attenuated atherosclerotic
plaque inflammation evaluated by FDG-PET/CT
in patients with IGT or type 2 diabetes. Because
there were no significant differences of blood glu-
cose control between the 2 groups, pioglitazone
may have anti-inflammatory properties in IGT or
haracteristics
les
Pioglitazone
(n  31)
Glimepiride
(n  21) p Value
22/9 17/4 NS
68.2 7.3 68.0 9.1 NS
64.4 12.1 65.6 11.0 NS
kg/m2 24.9 3.3 24.8 3.6 NS
e, cm 88.6 9.3 89.2 10.7 NS
sure, mm Hg 129 12 123 14 NS
ssure, mm Hg 71 9 69 9 NS
g/dl 111 26 119 24 NS
g/dl 50 12 51 13 NS
l 105 (85–131) 121 (81–165) NS
cose, mg/dl 121 (108–136) 131 (119–146) NS
ulin, U/ml 6.8 (4.8–10.9) 4.7 (3.6–8.5) NS
6.6 0.7 6.9 0.6 NS
P, mg/l 0.78 (0.37–2.07) 0.72 (0.41–1.51) NS
sease 3 (9.7) 6 (28.6) NS
sease 17 (54.8) 12 (57.1) NS
26 (83.9) 16 (76.2) NS
17 (54.8) 15 (71.4) NS
22 (71.0) 15 (71.4) NS
17 (54.8) 8 (38.1) NS
agent 11 (35.5) 13 (61.9) NS
16 (51.6) 15 (71.4) NS
5 (16.1) 4 (19.0) NS
 SD, median (interquartile range), or n (%).
-converting enzyme inhibitor; ARB  angiotensin II receptor blocker; CRP 
DL  high-density lipoprotein; LDL  low-density lipoprotein; NS  notdiabetic patients beyond glucose-lowering effects. sLaurberg et al. (21) reported that there was no
association between FDG uptake in atherosclerotic
plaque and the histological presence of plaque inflam-
mation, for example, the presence of macrophages in
apolipoprotein E knockout mice with FDG-
microPET. However, Rudd et al. (22) found that
most of the FDG accumulation in carotid arteries
corresponded to the macrophage-rich area of the
atherosclerotic plaque in 8 patients with symptomatic
carotid atherosclerosis. Moreover, Tawakol et al. (23)
demonstrated that there was a significant correlation
between FDG uptake within carotid atherosclerotic
plaques and macrophage staining from the corre-
sponding histological sections in 17 patients who
subsequently underwent carotid endarterectomy.
These observations suggest that FDG-PET is capable
of identifying and quantifying plaque inflammatory
cell activity in humans. Therefore, in this study, for
quantitative analysis of vascular inflammation, we
measured TBR values in the carotid arteries and
thoracic aorta by FDG-PET. The TBR value is a
quantitative parameter of glucose metabolic rate
within the vessels; thus, high TBR values could
indicate plaque inflammation. Further, as shown in
Figure 3, we have found here that FDG is accumu-
lated within the atherosclerotic plaques. These find-
ings are consistent with the concept that FDG-PET
is a reliable method for detecting inflammation within
the atherosclerotic plaques (17–20,22,23).
We limited analysis only to carotid arteries and
ascending aorta of the aortic arch (Fig. 2), because:
1) these vessels are responsible for atherothrombotic
stroke; and 2) the most striking effect of pioglita-
zone in the PROactive study was a decreased
incidence of stroke (6). In the CHICAGO and
PERISCOPE studies, 18-month pioglitazone
treatment prevented the progression of carotid or
coronary atherosclerosis compared with glimepiride
(8,9). In their studies, plasma glucose control by
pioglitazone was comparable to glimepiride for the
first 4 months from the beginning of the studies, and
became better than glimepiride thereafter. Therefore,
we compared the anti-inflammatory effect of piogli-
tazone versus glimepiride at 4 months of treatment.
In the present study, pioglitazone but not
glimepiride increased HDL-C level. Our findings are
consistent with those of many previous studies (4–9).
urther, multivariate analysis revealed that HDL-C
as independently associated with decreased plaque
nflammation evaluated by TBR in our subjects.
hese findings suggest that HDL-C–increasing ef-
ects of pioglitazone could mainly be involved in theTable 1. Patient C
Variab
Male/female
Age, yrs
Weight, kg
Body mass index,
Waist circumferenc
Systolic blood pres
Diastolic blood pre
LDL cholesterol, m
HDL cholesterol, m
Triglycerides, mg/d
Fasting plasma glu
Fasting plasma ins
Hemoglobin A1c, %
High-sensitivity CR
Cerebrovascular di
Coronary artery di
Hypertension
ACE-I/ARB
Dyslipidemia
Statin
Oral hypoglycemic
Antiplatelet agent
Current smoking
Values are n/n, mean
ACE-I  angiotensin
C-reactive protein; Huppression of atherosclerotic plaque inflammation in
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1115our patients. The finding was consistent with a pre-
vious publication showing that statin treatment was
associated with decreased plaque inflammation in
dyslipidemic patients, the extent of which was corre-
lated to the increase in HDL-C level (17). Moreover,
Figure 3. Treatment Effects on FDG Uptake in Atherosclerotic P
Treatment effects of pioglitazone and glimepiride on 18F-ﬂuorodeo
FDG-positron emission tomography/computed tomography with co
ment with (bottom) pioglitazone or (top) glimepiride. Note reducti
Table 2. Results of 4-Month Treatment With Pioglitazone and G
Pioglitazone
Parameters Baseline Follow-U
Body weight, kg 64.4 12.1 65.3 12.
Waist circumference, cm 88.6 9.3 90.1 9.1
Systolic BP, mm Hg 129 12 126 15
Diastolic BP, mm Hg 71 9 71 9
HDL cholesterol, mg/dl 49.7 12.4 55.3 13.
LDL cholesterol, mg/dl 111 26 109 27
Triglycerides, mg/dl 105 (85–131) 120 (82–151
Hemoglobin A1c, % 6.6 0.7 6.2 0.4
Fasting plasma glucose, mg/dl 121 (108–136) 111 (102–12
Fasting plasma insulin, U/ml 6.8 (4.8–10.9) 6.4 (4.2–9.6
High-sensitivity CRP, mg/l 0.78 (0.37–2.07) 0.51 (0.26–1
Values are mean  SD or median (interquartile range).
BP  blood pressure; other abbreviations as in Table 1.treatment (arrows).HDL-C not only promotes reverse cholesterol trans-
port, but also has anti-inflammatory and antioxidant
activity in humans, thereby protecting against athero-
sclerosis. These atheroprotective actions of HDL-C
may have reduced the atherosclerotic plaque inflam-
es
ucose (FDG) uptake in atherosclerotic plaques. Representative
st media images (left) at baseline and (right) after 4-month treat-
n FDG uptake in the atherosclerotic plaque with pioglitazone
epiride in the Study Patients
Glimepiride
p Value Baseline Follow-Up p Value
Ab
0.05 65.6 11.0 65.9 10.7 NS
0.01 89.2 10.7 89.3 10.2 NS
NS 123 14 123 14 NS
NS 69 9 67 10 NS
0.01 51.0 13.2 53.1 12.7 NS
NS 119 24 118 20 NS
NS 121 (81–165) 123 (90–209) NS
0.01 6.9 0.6 6.5 0.5 0.01
0.01 131 (119–146) 121 (112–134) 0.01
NS 4.7 (3.6–8.5) 5.9 (3.8–7.8) NS
0.01 0.72 (0.41–1.51) 1.04 (0.5–2.10) 0.05laqu
xygl
ntra
on ilim
p
solute Change From
Baseline p Value
4 NS
NS
NS
NS
8 NS
NS
) NS
NS
0) NS
) NS
.02) 0.01
. N.S
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1116mation in our subjects. However, the recent results of
the clinical trial AIM-HIGH (Atherothrombosis In-
tervention in Metabolic Syndrome With Low HDL/
High Triglycerides: Impact on Global Health Out-
Figure 4. Changes in TBR After 4-Month Treatment With Pioglit
(Top) The target-to-background ratio (TBR) was evaluated in individ
analysis. (Bottom) Change (∆) in TBR from baseline. Bar  1 SEM
Table 3. Factors Associated With Extent of Target-to-Backgroun
Analysis in All Subjects
Factors
Univariate
Coefﬁcient p Va
∆body weight 0.036 N
∆waist circumference 0.022 N
∆systolic blood pressure 0.111 N
∆diastolic blood pressure 0.129 N
∆HDL-cholesterol 0.332 0
∆LDL-cholesterol 0.003 N
∆triglycerides* 0.018 N
∆hemoglobin A1c 0.026 N
∆fasting plasma glucose* 0.060 N
∆fasting plasma insulin* 0.168 N
∆high-sensitivity CRP* 0.267 0
R2 — —
*Log-transformed value was used.
Abbreviations as in Table 1.comes Trial), in which 34% of subjects had diabetes,
have demonstrated a lack of benefit in hard cardiovas-
cular events with improvements in HDL-C level (24).
Our results demonstrated that pioglitazone attenuated
ne or Glimepiride
patients at baseline and after 4-month treatment for quantitative
.  not signiﬁcant.
atio by Univariate Analysis and Multiple Stepwise Regression
Multivariate
Coefﬁcient F Value p Value
— — —
— — —
— — —
— — —
0.378 2.666 0.01
— — —
— — —
— — —
— — —
— — —
0.225 1.708 NS
0.143 — —azo
uald R
lue
S
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S
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1117atherosclerotic plaque inflammation in patients with
IGT or type 2 diabetes. Although there was a positive
relationship between change in TBR and change in
HDL-C levels, the decrease in the inflammation may
not be necessarily due to the increase in HDL-C.
In the present study, hsCRP level was decreased
in the pioglitazone group, whereas it increased in
the glimepiride group. Further, univariate analysis
revealed that reduction of hsCRP level was corre-
lated with the decrease in atherosclerotic plaque
inflammation in our subjects. However, the signif-
icant correlation between hsCRP and plaque in-
flammation was lost after adjustment for HDL-C
level. These observations suggest attenuation of
plaque inflammation by the treatment of pioglita-
zone observed here could be ascribed to its HDL-
C–elevating properties, rather than its hsCRP-
lowering effects. Another possibility is that because
serum hsCRP reflects systemic inflammation, sub-
tle change in plaque inflammation may not be
revealed.
Study limitations. First, the small sample size may
limit our interpretation and discussion. Second, we
included the patients receiving aspirin, renin-
angiotensin system inhibitors, and statins, which may
confound the present results. Further, only one-half of
the study patients were receiving statins, and with
greater statin use at baseline, there is the possibility for
different study results. Third, we have previously
shown that increased vascular inflammation evaluated
by FDG-PET was associated with the metabolic risks
(18). So, we can not completely exclude the possibility
that pleiotropic effects other than an HDL-C–
dependent mechanism could mediate the anti-
inflammatory effect of pioglitazone on the athero-Granda-Ayala R, Lee TR, Fonseca Lancet 2005;366:12administration and observation periods might provide
us much clearer evidence of the anti-inflammatory and
antiatherogenic properties of pioglitazone. Fifth, the
study was not powered to detect a difference in
cardiovascular endpoints. Additional study will be
needed to address whether attenuation of plaque
inflammation evaluated by FDG-PET could predict
future cardiovascular events, especially stroke, in hu-
mans. Finally, although there were no observed ad-
verse effects of heart failure among patients receiving
pioglitazone treatment in our study, we should men-
tion that pioglitazone has a black box warning from
the Food and Drug Administration warning against
use for patients with heart failure (25).
C O N C L U S I O N S
Our present study suggests that pioglitazone could atten-
uate atherosclerotic plaque inflammation in patients with
IGT or type 2 diabetes in a glucose-lowering indepen-
dent manner. Pioglitazone may be a promising strategy
for the treatment of atherosclerotic plaque inflammation
in IGT or type 2 diabetic patients.
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